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Abstract: Retinal hemangioblastomas are the most common manifestation of Von Hippel-Lindau (VHL) disease [1-3]. 
While peripheral retinal hemangioblastomas may be treated by thermal laser treatment or cryotherapy, optic nerve and 
macular lesions are more difficult to treat [4, 5]. Based on the theoretical benefit of administering anti-VEGF treatment, 
intra-vitreally administered bevacizumab (Avastin, a general pan-VEGF inhibitor) is attractive [6, 7]. 
Several short-term case series using ranibizumab (Lucentis, mAb fragment of bevacizumab with stronger affinity for 
VEGF-A) have shown it has promising but minimal success on most VHL-related hemangioblastomas [8, 9]. A 
comprehensive study by Wong et al. examined 5 patients over a period up to 61 weeks (47 ± 14 weeks) while Michels et 
al. examined one patient over a period of 4 months. Due to the short-term nature of these studies, we attempted long-term 
bevacizumab treatment over 60 months in a monocular subject with progressive visual loss due to a VHL associated 
macular and optic nerve hemangioblastoma. Over the treatment regimen of 15 injections, visual acuity improved 25 
letters, OCT thickness improved from 646 um to 424 um, and structural lesions stabilized while exudates and edema 
resolved. 
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INTERVENTION 
  A 33-year-old male with a long history of VHL 
associated tumors including benign cysts on liver, kidneys 
and cerebellum presented with multiple large retinal 
hemangioblastomas in his remaining right eye. We 
successfully treated a large peripheral hemangioblastoma 
with cryotherapy and a smaller equatorial lesion with 
thermal laser. However, significant macular thickening with 
moderate hard exudates were present due to an optic nerve 
lesion with extension towards the fovea (Fig. 1A). We 
treated the lesion with a total of 15 bevacizumab injections 
over a period of 60 months. Visual acuity (VA), appearance 
on fluorescein angiogram (FA), and optical coherence 
tomography (OCT) measurements were used as indicators of 
treatment success. VA was measured using a Reichert eye 
chart and was converted to visual acuity notation letters in 
Fig. (2). 
RESULTS 
  Baseline VA was 20/100. Due to worsening vision, 
continued leakage on angiography and macular thickening, 
the patient underwent treatment as outlined in Fig. (2). At 12 
months and after treatment with thermal laser therapy, 
cryotherapy and intravitreal kenalog, given the lack of 
biomicroscopic or angiographic response, the patient began 
receiving intravitreal bevacizumab (Avastin 1.25 mg in 0.05 
cc) treatments at regular intervals. At 24 month follow up,  
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VA improved to 20/30, the structural lesion stabilized and 
the exudates and edema resolved (Fig. 1B). The OCT 
showed only a partial improvement in thickness (646 um to 
414 um) likely due to the presence of structural changes in 
the retina (Fig. 3A, B). On final examination, after a follow 
up of 60 months and 15 total bevacizumab injections, VA 
showed minimal regression to 20/40 and remained markedly 
better than VA on presentation. The structural lesion 
remained stable and no new exudates or edema were 
appreciated (Fig. 1C). OCT showed that thickness remained 
substantially decreased from initial presentation (Fig. 3C). 
No systemic or ocular adverse events related to any of the 
treatments were noted. 
DISCUSSION 
  Macular and optic nerve lesions due to VHL associated 
hemangioblastomas have generally been difficult to treat. As 
one of the major mechanisms of disease is due to the poor 
regulation of VEGF (among others) production, using a pan-
VEGF blocker over the long term is both logical and 
potentially helpful. To our knowledge, this is the longest-
term study involving pan anti-VEGF therapy to treat VHL. 
While it is difficult to compare the results between the other 
two studies using VEGF suppression by pegaptanib or 
semaxanib with the current single case study, it is instructive 
to note that even the best subject in Wong’s series (among 
the five total subjects) treated with pegaptanib did not 
achieve as significant a reduction in central macular 
thickness as our patient with bevacizumab did. 
 Wong  et al. examined the effects of ranibizumab on five 
patients with VHL associated hemangioblastomas in a short- 
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Fig. (1). Fundus Photographs and Fluorescein Angiograms at 0, 24, and 60 months. 
 
Fig. (2). A schematic representation at 0, 24, and 60 months of best-corrected visual acuity (BCVA) and central subfield thickness (μm), as 
measured by optical coherence tomography (OCT), with designated mode of treatment, OD. Open symbols indicate extra ocular treatments 
and closed symbols indicate intraocular treatments, and are as follows: () - Thermal laser therapy, () – Intravitreal Triamcinolone, () – 
Cryotherapy and () - Avastin. 68    The Open Ophthalmology Journal, 2010, Volume 4  Hrisomalos et al. 
term case series with follow-up periods up to 61 weeks [8]. 
They concluded that ranibizumab had minimal effects on 
most lesions but noted that efficacy was seen in their patient 
with the smallest lesion and the least exudation. Patients in 
their data set showed an average decrease of 9+/-20 letters. 
Conversely, our patient experienced an improvement in VA 
of 25 letters while our patient’s lesions initially improved 
then remained stable. Major differences between the two   
 
studies were the number of anti-VEGF injections 
administered and agent used; their patients had an average of 
10.0 +/-3.1 injections of ranibizumab while our patient had 
15 injections of bevacizumab. A single case study by 
Michels et al. also demonstrated slow regression of activity 
in hemangioblastoma lesions following ranibizumab 
treatment however follow-up was relatively short at 4 
months and only involved 3 intravitreal injections. 
 
Fig. (3). (A) Optical coherence tomography of the right eye before intravitreal bevacizumab (Avastin) treatment showed significant cystoid 
macular edema. Central subfield thickness was 646 μm. (B) After treatment with Avastin (x4), the edema was substantially improved and 
retinal thickness was reduced to 414 μm. (C) At 60 months, edema remained largely resolved with retinal thickness at 424 μm. Long-Term Use of Avastin for VHL Hemangioblastomas  The Open Ophthalmology Journal, 2010, Volume 4    69 
  Another probable benefit of intermittent bevacizumab 
treatment appears to be the suppression of new 
hemangioblastomas. This subject was carefully assessed for 
such tumors throughout his follow up, and did not develop 
any additional hemangioblastomas in the peripheral retina, 
on fundus contact lens examination as well as with 
angiography of the periphery. Wong et al. observed an 
additional lesion arising de novo in only one out of five 
patients [8]. Documentation in the literature suggesting the 
untreated rate of new lesions arising does not explicitly exist. 
Chew described the course of several patients with ocular 
VHL disease who were not treated with anti-VEGF agents 
that developed additional peripheral lesions throughout their 
follow-up periods
1. However, two patients that were treated 
with pegaptanib did not develop any new lesions during 
treatment or follow-up periods [1]. 
  Based on subjects with age-related macular degeneration, 
where treatment with bevacizumab often shows excellent 
results, it appears that a similar benefit may apply to 
treatment with bevacizumab in cases of VHL associated 
hemangioblastomas. The structural changes due to the 
development of these retinal hemangioblastomas include 
large cells containing intractoplasmic lipid inclusions, 
reactive glial cells, as well as tumorlet cells [10]. Based on 
OCT findings, as well as clinical observation, it appears that 
VEGF suppression with bevacizumab does not appreciably 
affect these structural changes. Until more elegant solutions 
to VHL hemagioblastomas are developed, localized VEGF 
blocking therapy with bevacizumab (or ranibizumab) may be 
an interim solution for macular and optic nerve lesions. 
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